A multiyear agreement has been reached by ArcherDX and Illumina to co-market future ArcherDX in vitro diagnostic products with Illumina's NextSeq 550Dx and MiSeq Dx instruments. The partnership is likely to begin with ArcherDX's Stratafide pan-solid tumor test, a companion diagnostic that determines actionable genomic alterations in blood or tissue samples.
ArcherDX teams up with Illumina on IVDs
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.